[Evaluation on the safety and immunogenicity of split influenza virus vaccine].

Objective: To evaluate the safety and immunogenicity of split influenza virus vaccine made in changchun institute of biological products.

Methods: Cluster samples were selected by random to carry out the single center, open clinical trial.

Results: After one dose injection, the rate of local reaction were 0.

Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.

Background: The current influenza pandemic calls for a safe and effective vaccine. We assessed the safety and immunogenicity of eight formulations of 2009 pandemic influenza A H1N1 vaccine produced by ten Chinese manufacturers.

Methods: In this multicentre, double-blind, randomised trial, 12 691 people aged 3 years or older were recruited in ten centres in China.